1. Home /
    2. Altai Protocol Library /
  2. New Reference: Nivolumab plus cabozantinib in first-line treatment for advanced renal cell carcinoma

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara
Altai Protocol Library

New Reference: Nivolumab plus cabozantinib in first-line treatment for advanced renal cell carcinoma

New Reference: Nivolumab plus cabozantinib in first-line treatment for advanced renal cell carcinoma
Study:
  • Open-label, randomised, phase 3 trial (CheckMate 9ER)
  • Previously untreated advanced or metastatic clear-cell renal cell carcinoma
  • Nivolumab 240 mg/2 weeks plus cabozantinib 40 mg/day (N:323) or sunitinib 50 mg/day, 4 weeks per 6-week cycle (N:328)
Efficacy:
  • mOS:37·7 m vs 34·3 m (HR:0·70 [95% CI 0·55–0·90], p=0·0043)
  • mPFS:16·6 m vs 8·3 m (HR 0·56 [95% CI 0·46−0·68], p<0·0001)
Safety:
  • Grade >= 3 AEs: 65% vs 54%
  • Grade >=3 AEs: HT 13% vs 12%, palmar–plantar erythrodysaesthesia 8% vs 8%, diarrhoea 7% vs 5%
  • Treatment-related serious AEs 22% vs 10%
  • One treatment-related death occurred with sunitinib

Lancet Oncol. 2022 Jul;23(7):888-898.

Motzer, Robert J et al. “Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.”

https://doi.org/10.1016/s1470-2045(22)00290-x

Reviewed by Hasan Çağrı Yıldırım, MD on Jul 05, 2022

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More